Mirum Gains 35% in 3 Months: How Should You Play the Stock?

Mirum Pharmaceuticals (MIRM) shares surged 35% over the past three months, significantly outperforming the market, driven by robust commercial performance. This includes a 71% year-over-year increase in Livmarli sales to $73.2 million in Q1 2025 and strong contributions from acquired bile acid products, leading the company to raise its 2025 revenue guidance to $435-$450 million. While Mirum is advancing pipeline candidates like volixibat and a new Fragile X syndrome treatment, its heavy reliance on Livmarli and intense competition from rivals, particularly Ipsen's Bylvay, present ongoing challenges despite the positive commercial momentum.

Analysis

Mirum Pharmaceuticals (MIRM) has demonstrated significant commercial momentum, reflected in a 35% share price increase over three months, substantially outperforming its industry's 6.9% rise. This performance is primarily fueled by its lead product, Livmarli, which saw sales surge 71% year-over-year to $73.2 million in the first quarter of 2025. This robust demand, complemented by a 47% YoY growth in sales from its acquired bile acid product portfolio, prompted management to raise its full-year 2025 revenue guidance to a range of $435-$450 million. Despite this strong top-line growth, several risks temper the outlook. The company remains heavily dependent on Livmarli, creating a significant concentration risk. Furthermore, it faces direct and substantial competition from Ipsen's Bylvay, an IBAT inhibitor targeting the same markets. The stock's valuation appears stretched, with a price-to-book ratio of 11.21x, far exceeding the industry average of 3.08x. This high valuation is juxtaposed with mixed analyst estimates, as the consensus loss-per-share forecast for 2026 has widened, suggesting potential headwinds on the path to profitability.

Key Decisions for Investors

• Investors should recognize that while Mirum's strong commercial execution and upwardly revised revenue guidance are bullish signals, the stock's elevated valuation already prices in significant future success.
• The high dependency on Livmarli and intense competition from Ipsen's Bylvay represent key risks that warrant close monitoring of market share dynamics in the ALGS and PFIC treatment spaces.
• Upcoming catalysts, particularly the top-line data for volixibat expected in the second quarter of 2026, are critical, and any clinical setbacks could significantly impact the stock given the mid-stage nature of the broader pipeline.
• The widening loss-per-share estimate for 2026 is a cautionary signal, suggesting investors should scrutinize the company's expense trajectory and timeline to profitability.